SpringWorks Therapeutics PT Cut to $44.00

Trending News 🌧️

Springworks Therapeutics Intrinsic Stock Value – SPRINGWORKS ($NASDAQ:SWTX): SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing life-changing therapies for patients with severe rare diseases and cancer. The company’s lead product candidate, nirogacestat, is in development for the treatment of desmoid tumors and advanced soft tissue sarcoma.

Price History

On Monday, shares of SpringWorks Therapeutics, Inc. were down 1.8% after the company’s stock was cut to $44.00 by analysts at Piper Sandler. The stock opened at $24.40 and closed at $24.00 for the day. This follows a mostly negative media coverage of the company.

VI Analysis – Springworks Therapeutics Intrinsic Stock Value

Sprinworks Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of novel therapies for the treatment of rare diseases with high unmet medical needs. The Company’s product candidates include SPINRAZA, which is used for the treatment of spinal muscular atrophy ; and Firdapse, which is used for the treatment of Lambert-Eaton myasthenic syndrome .

VI Peers

The company is focused on developing and commercializing therapies for the treatment of rare and underserved diseases. SpringWorks Therapeutics Inc’s competitors include Aadi Bioscience Inc, Avalo Therapeutics Inc, and Immunic Inc.

– Aadi Bioscience Inc ($NASDAQ:AADI)

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of cancer and other diseases. The company’s lead product candidate is AB-101, a small molecule inhibitor of the PI3K/mTOR pathway, which is in Phase I clinical trials for the treatment of solid tumors. Aadi Bioscience Inc has a market cap of 317.87M as of 2022, a Return on Equity of -28.05%.

– Avalo Therapeutics Inc ($NASDAQ:AVTX)

Avalo Therapeutics Inc is a clinical stage biopharmaceutical company developing novel cancer therapies. The company’s market cap as of 2022 is 50.93M and its ROE is 729.23%. Avalo’s pipeline of products includes two clinical stage programs: AVL-292, a first-in-class, small molecule inhibitor of checkpoint kinase 1 (Chk1) for the treatment of solid tumors, and AVL-181, a first-in-class, small molecule inhibitor of checkpoint kinase 2 (Chk2) for the treatment of hematologic malignancies.

– Immunic Inc ($NASDAQ:IMUX)

Immunic, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing oral therapies for the treatment of immune-mediated diseases. Its pipeline includes IMU-838 that is in Phase II clinical trial for the treatment of plaque psoriasis and atopic dermatitis; and IMU-935, which is in Phase I clinical trial for the treatment of autoimmune diseases. The company was founded by Daniel M. Adelman, Michael J. Brenner and William T. Symonds on December 15, 2006 and is headquartered in New York, NY.

Summary

Investing in Springworks Therapeutics could be a risky proposition, as the company has yet to bring any products to market and is still in the early stages of development.

However, the potential rewards could be significant, as the company is working on treatments for rare diseases that currently have no effective treatments. Before investing in Springworks Therapeutics, it is important to do your research and understand the risks involved. The company is still in the early stages of development, and it remains to be seen if its products will be successful in the market. However, the potential rewards could be significant, so investors should weigh the risks and potential rewards carefully before making a decision.